Florida regenerative medicine compliance — what FDA, AHCA, and the Board of Medicine expect on file in 2026.

The 2026 regenerative-enforcement reality

For most of the past decade, regenerative medicine in Florida grew faster than the regulatory framework that governs it. PRP, exosome injections, peptide-based protocols, and stem-cell-adjacent therapies moved from research clinics into retail wellness practices. In 2026 the gap between market practice and federal enforcement posture is narrower, sharper, and more public than it has ever been.

Four developments define the current landscape:

• The FDA exosome warning-letter campaign. Between 2019 and 2025 FDA issued multiple warning letters and public safety communications to clinics and manufacturers marketing exosome products. FDA's consistent position has been that exosome products derived from human cells or tissues are biologics that require an approved Biologics License Application (BLA) before lawful marketing. As of May 2026, no exosome product is FDA-approved for any therapeutic indication. The current warning-letter record is published at the FDA warning letter index.
• The end of HCT/P enforcement discretion. Following the 21st Century Cures Act of 2016, FDA published guidance for the regenerative-medicine HCT/P sector and granted a three-year enforcement-discretion period that was extended through May 2021. Since the discretion period ended, FDA has issued numerous warning letters against products that fall outside the § 361 / 21 CFR 1271.10 criteria for low-risk HCT/Ps — especially allogeneic, more-than-minimally- manipulated, and non-homologous-use products marketed as "stem cell" therapies.
• Peptide-pharmacy enforcement escalation. In 2023–2025, FDA and DEA jointly escalated enforcement against compounding pharmacies and clinics dispensing research peptides marketed for performance, recovery, or longevity. FDA's Pharmacy Compounding Advisory Committee (PCAC) has periodically reviewed nominations to the § 503A "do-not-compound" list. The legal status of individual peptides moves; a peptide that was available through compounding pharmacies in 2022 may not be available in 2026, and clinics that source from pharmacies later cited by FDA carry residual exposure.
• Malpractice carrier hardening. Carriers that previously underwrote regenerative clinics on aesthetic-tier policies have moved many regenerative procedures to a separate risk pool with higher premiums, stricter underwriting questionnaires, and renewal-week document requests that aesthetic clinics rarely face. A clinic that cannot produce the regenerative consent template, the chain-of-custody log, and the FDA-status disclosure on demand often sees a non-renewal.

The regulatory stack that governs Florida regenerative clinics

There is no single statute or rule that governs regenerative medicine in Florida. The applicable law is layered, federal-first, and state-second. The layers a Florida regenerative clinic has to track simultaneously:

• 21 CFR Part 1271 — HCT/P regulations. The FDA regulation governing Human Cells, Tissues, and Cellular and Tissue-Based Products. § 1271.10 sets the four criteria a product must meet to qualify as a low-risk HCT/P regulated under § 361 alone (no IND or BLA required). Products that fail the criteria are regulated as drugs or biologics and require premarket approval. Read the current text at the ECFR — 21 CFR Part 1271.
• FDA warning letter index. The single most useful real-time signal for regenerative compliance. FDA publishes warning letters in a searchable index; a vendor that lands on the list is, at minimum, a vendor a clinic should immediately review with its attorney. The index is at the FDA Warning Letters page.
• 21 USC § 352 — drug labeling. The federal prohibition on misbranding requires drug labeling that accurately reflects the FDA approval status, intended use, dose, and warnings. Marketing a regenerative product in ways that go beyond what the label supports is a misbranding exposure independent of the product's underlying approval status.
• § 458.348 — Florida supervisory agreement. The statute that anchors ARNP and PA delegated medical practice. Regenerative procedures are delegated medical acts; the supervisory protocol has to authorize each one specifically. See our § 458.348 explainer.
• § 458.331(1)(t) — Florida standard of care. The provision under which the Florida Board of Medicine reviews physician practice. A regenerative procedure performed below the standard of care — with sloppy documentation, no Good Faith Exam, no informed consent, no off-label disclosure — is reviewable here.
• Florida Administrative Code Rule 64B8-9.009 — Good Faith Exam. The Board of Medicine standard for the practitioner-patient encounter that establishes the relationship and authorizes a delegated procedure. Regenerative procedures are inside this framework. See our Good Faith Exam explainer.
• § 400.9905 — AHCA Health Care Clinic licensure. The Florida statute that defines which clinics need AHCA HCC licensure and what documentation is sampled in survey. See our AHCA HCC explainer.
• Board of Medicine stem-cell guidance. The Florida Board of Medicine has published advisory positions and opinion letters on regenerative practice. Consult your healthcare attorney for the current text of any Board advisory and how it applies to your clinic's specific protocols.

PRP vs. exosomes vs. peptides vs. stem cells — what differs

The four product categories most often grouped as "regenerative medicine" have very different regulatory profiles. Treating them as a single category is the most common compliance error we see in Florida intake calls.

What "minimally manipulated" means under 21 CFR 1271.10

The single most important test inside the HCT/P framework is whether a product is minimally manipulated. FDA defines minimal manipulation differently for structural tissues (where it means processing that does not alter the original characteristics relating to the tissue's utility for reconstruction, repair, or replacement) and for cells or non-structural tissues (where it means processing that does not alter the relevant biological characteristics of cells or tissues).

The companion criteria under § 1271.10 are: homologous use (the product performs the same basic function in the recipient as it did in the donor); no combination with another article (with limited exceptions for storage and preservation agents); and autologous use, allogeneic same-day use, or another narrow exception for products that depend on metabolic function.

A product that meets all four criteria is regulated under § 361 alone — FDA registration, donor-eligibility, and current Good Tissue Practice (cGTP) requirements apply, but no IND or BLA is needed. A product that fails any criterion is regulated as a drug or biologic, requires IND or BLA, and is subject to the full force of the food, drug, and cosmetic framework.

FDA's Tissue Reference Group publishes product-specific classification letters. When the classification is ambiguous, the defensible practice is to seek a Tissue Reference Group consult or a written healthcare-attorney opinion before clinical use — not to read the regulation in the procedure room.

The off-label / experimental-use consent question

For regenerative procedures, the consent form is the document FDA, the Board of Medicine, and malpractice carriers all look at first. A generic cosmetic-injectable consent is not adequate for a regenerative product.

The elements a regenerative consent commonly includes:

1. The exact product being administered. Manufacturer, lot, expiry, and any cleared-device or product-classification information.
2. The FDA approval status of the product. A plain-English statement of whether the product is FDA-approved, FDA-cleared, regulated as an HCT/P under § 361, or unapproved.
3. The indication being treated. If the use is off-label or experimental, that fact is identified explicitly — not buried.
4. The evidence basis the practitioner is relying on. Published literature, clinical experience, or absence of clinical data — whichever is honest.
5. The foreseeable risks. Adverse-event categories specific to the product class — infection, immune reaction, neurologic and vascular events, contamination risks, unknown long-term effects for products without long-term safety data.
6. The patient's acknowledgment. Signed and dated by the patient, with an identifiable patient (full legal name + DOB or MRN — not initials) and a witness or practitioner counter-signature.
7. Alternatives, including the option to not treat. A regenerative consent that does not present alternatives is not credible.

Template consents copied from a vendor's marketing packet are the most common citation pattern in our intake review. Vendor-supplied consents almost never adequately disclose FDA status or off-label use. A clinic-specific consent template, reviewed by a healthcare attorney, is the defensible baseline.

Chain-of-custody — the regenerative documentation core

Chain-of-custody is the recordkeeping practice that links every regenerative product from its source to the patient who received it. In a regenerative-medicine inspection, chain-of-custody is what an FDA investigator typically asks for within the first hour.

A defensible chain-of-custody record for a regenerative product includes:

• The source — the manufacturer, the lot number, the production date or reference, and the certificate of analysis if applicable.
• The shipping and receiving — date received, condition on arrival, cold-chain documentation if temperature-sensitive, signature of the receiving staff.
• The storage — location, temperature log, access controls.
• The preparation — date and time of preparation, the practitioner or staff who prepared it, the volume or dose drawn.
• The administration — patient identifier (full legal name + DOB or MRN), practitioner administering, dose, site, route, date and time.
• The residual handling — what happened to any unused product (returned, discarded, biohazard log).

A clinic that can produce this chain for every regenerative procedure has the documentation backbone an FDA inspection requires. A clinic that cannot reproduce the chain for a procedure performed six months ago is at material exposure.

The FDA inspection-response pack — what to assemble before you need it

FDA inspections of regenerative clinics are document-heavy. The practical defense is a pre-assembled inspection-response pack that can be produced within hours, not days. The pack typically includes:

• The regenerative product log — every product on premises, with lot, expiry, manufacturer, FDA classification status, and source documentation.
• The chain-of-custody records for products used in the prior 12 months.
• The consent template in current use, and signed consents from a sample of recent procedures.
• The Good Faith Exam records for the sampled procedures.
• The supervisory protocol authorizing the procedures, with the medical director's signature and the supervised practitioners listed.
• The standing orders for each regenerative product category, with prescriber identification and current dates.
• The vendor BAAs and contracts — if any vendor handles PHI in the supply chain.
• The adverse-event log — with patient identifier, event, date, reporting status, and follow-up.
• The training records for the staff performing regenerative procedures, including documented regenerative-medicine continuing education.
• The FDA warning letter scan — the current state of any vendor in the clinic's supply chain.

The malpractice renewal layer

Regenerative carriers ask renewal-week questions that aesthetic carriers don't. In our intake calls with Florida regenerative clinics, the most common renewal questionnaire items:

• List every regenerative product administered in the past 12 months, with manufacturer and lot information.
• Confirm whether each product is FDA-approved, FDA-cleared, a § 361 HCT/P, or unapproved.
• Produce the consent template used for each product category, with FDA-status disclosure.
• Confirm the supervising physician's regenerative-medicine training and credentialing.
• Disclose any adverse events, FDA inquiries, AHCA citations, or Board complaints in the preceding year.
• Confirm chain-of-custody documentation is maintained.
• Confirm the clinic monitors the FDA warning letter index for vendor changes.

The renewal pack is best assembled 60 days before renewal. A clinic that scrambles in renewal week is the clinic that gets a non-renewal or a sharp premium increase.

What ProofOps Medical does for a Florida regenerative clinic

ProofOps Medical is a Florida-only, done-for-you compliance department — your fractional compliance desk, working across 9 frameworks (AHCA, Board of Medicine, FDA, DEA where applicable, OSHA, HIPAA, malpractice, vendor BAA, and adverse-event) on top of your existing EMR and scheduling. Biologic materials — exosomes, stem-cell HCT/Ps, PRP — sit in the highest-scrutiny corner of Florida practice, and a single gap in the chain-of-custody or the consent file is the kind of thing that turns an FDA visit into a Board of Medicine inquiry into your medical director's license. Technology does the heavy lifting; a real person reviews and signs off before anything is filed. You don't lift a finger. For regenerative clinics specifically, here is what we handle for you:

• Lot-track every vial of PRP kit, exosome preparation, peptide vial, or HCT/P unit through to the patient who received it. The chain-of-custody record reconciles weekly and surfaces any gap.
• Maintain off-label / experimental consent forms with patient acknowledgment of FDA approval status. Consent templates are kept current with vendor and indication changes; signed consents are paired to procedures inside the chart.
• Document the source of every regenerative product — manufacturer, lot, expiry, certificate of analysis if applicable, and shipping/receiving log.
• Watch the FDA warning letter index weekly and flag any vendor in your supply chain that lands on it, so you and your healthcare attorney can review immediately.
• Capture the Good Faith Exam for every regenerative procedure — the standard of care under Florida Administrative Code Rule 64B8-9.009 — including practitioner identification, history, exam, risk-benefit discussion, and authorization.
• Log the investigational and clinical protocol for every biologic procedure — the standing order, the supervisory protocol authorizing the specific procedure, and any IND coverage where the clinic treats under an investigational protocol — so the authorization chain behind each exosome, stem-cell, or PRP administration is intact and dated.
• Insulate your medical director with weekly, human-reviewed chart samples. A real person reviews each sample — with extra scrutiny on off-label and experimental indications — and surfaces any chart that needs additional documentation before it could be considered defensible. The aim is that nothing reaches a Board investigator that your medical director has not already seen, signed, and stood behind.
• Maintain the FDA inspection-response pack — regenerative product log, consent forms, MD assessment, vendor BAAs, training records, adverse-event log — so it is producible within hours, not days.
• Build the malpractice-renewal exhibit 60 days before renewal. Regenerative carriers ask for more than aesthetic carriers, and the exhibit is structured to anticipate the questionnaire.

Pricing for Florida regenerative clinics

ProofOps Medical pricing is the same across verticals. Regenerative clinics most often start on Lighthouse 5 to pressure-test the workflow, and graduate to Managed Evidence once volume justifies the recurring cadence.

• Lighthouse 5 — $0/mo for the first 30 days + $1,195 Historical Compliance Migration & Audit, then a locked $599/mo founding rate. Your five core compliance workflows, set up on your EMR and reviewed by a real person.
• Managed Evidence — $999/mo + $1,795 setup. The full done-for-you compliance department with a monthly inspection-ready binder and a weekly, human-checked medical-director sample.
• Multi-Location — $1,695/mo + $599/location + $2,495 setup. The Managed Evidence service with cross-location reconciliation and a single inspection-ready report per location and consolidated.

Detailed pricing at /pricing. Florida only.

Frequently asked questions

Are exosomes FDA-approved in 2026?

No. As of May 2026, no exosome product is FDA-approved for any therapeutic indication. FDA has consistently taken the position that exosome products derived from human cells or tissues are biologics requiring an approved Biologics License Application (BLA) before lawful marketing. Between 2019 and 2025, FDA issued multiple warning letters and public safety communications targeting unapproved exosome products. The current FDA warning letter record is at the FDA Warning Letters page. Verify any specific product status with your healthcare attorney before clinical use.

Can Florida med spas legally inject PRP?

PRP prepared from a patient's own blood and administered to that same patient on the same day has generally been treated by FDA as falling within the HCT/P exception under 21 CFR 1271.10 — the "minimally manipulated," "homologous use," "no combination with another article," and "autologous same-day" criteria. FDA has not, in 2026, classified autologous same-day PRP as a drug requiring approval. The exception is narrow and fact-specific, though: combining PRP with another biologic, using non-autologous components, using PRP for non-homologous indications, or processing PRP through a third-party lab can move the product outside § 1271.10. Confirm any specific clinical use with your medical director, your PRP-kit manufacturer's regulatory documentation, and your Florida healthcare attorney.

What peptides can Florida clinics legally compound or administer in 2026?

Specific legal status varies peptide-by-peptide and is moving — verify each peptide with your compounding pharmacist and your healthcare attorney before clinical use. FDA's Pharmacy Compounding Advisory Committee periodically reviews and publishes "do-not-compound" nominations under § 503A. Several research peptides commonly marketed for performance or longevity — including BPC-157, TB-500, and certain GHRH analogs — have been the subject of FDA review during 2023–2025, and FDA and DEA have escalated peptide-pharmacy enforcement during the same window. A peptide available through compounding pharmacies in 2022 is not necessarily available in 2026. ProofOps Medical does not maintain a legal list of compoundable peptides — that judgment belongs to the prescriber, the pharmacist, and a healthcare attorney.

What documentation does FDA ask for during an inspection of a Florida regenerative clinic?

A typical FDA inspection of a regenerative clinic requests source documentation for every regenerative product on premises (manufacturer, lot, expiry, chain-of-custody, certificate of analysis), the clinical-use records for those products (patient identifier, indication, dose, prescribing or supervising practitioner, signed consent), the consent forms used for off-label or experimental indications (with explicit acknowledgment of FDA approval status), the supervisory protocol and standing-order chain, the Good Faith Exam record for each procedure, and any IND-related documentation if the clinic is treating under an investigational protocol. Missing chain-of-custody and template-only consent forms are the most common citation patterns.

Who can administer regenerative therapies in Florida?

A regenerative procedure is a delegated medical act under Florida law. A Florida-licensed MD or DO may perform it directly. An ARNP operating under a written supervisory protocol that includes the specific procedure (§ 458.348) may perform it under that protocol. A PA operating under § 458.347 with a protocol that includes the procedure may perform it. A registered nurse may administer under a supervising practitioner's order once the Good Faith Exam and supervisory protocol are on file, but the GFE and authorization step must come from a qualified prescriber. Estheticians and unlicensed staff may not perform regenerative injections.

What's the malpractice exposure on regenerative procedures vs. aesthetic injectables?

Malpractice carriers generally treat regenerative procedures as a higher-risk category than standard cosmetic injectables — particularly for off-label biologics, stem-cell-adjacent products, and peptides not FDA-approved for the indication. Carriers commonly ask at renewal for the consent template used for each regenerative product, the FDA approval status disclosed to the patient, the chain-of-custody log for the product, the prescriber's regenerative-medicine training and credentialing, adverse-event logs, and a copy of the supervisory protocol. A clinic that cannot produce these in renewal week often sees a premium increase or non-renewal. Confirm carrier-specific requirements with your broker each cycle.

What's a "minimally manipulated" tissue product under 21 CFR 1271?

21 CFR 1271 governs HCT/Ps. To qualify as a low-risk § 361 HCT/P, a product must be (a) minimally manipulated, (b) intended for homologous use, (c) not combined with another article (with limited exceptions), and (d) autologous, allogeneic same-day, or another narrow exception for products dependent on metabolic function. FDA's enforcement-discretion period for products that did not clearly meet these criteria ended in May 2021. The Tissue Reference Group can be consulted for product-specific classification. Confirm any specific product's classification with the manufacturer and your healthcare attorney before use.

How do I document off-label use of a regenerative product?

Off-label use of an FDA-approved product is generally lawful when done in good faith based on medical evidence, but the documentation standard is high in a regenerative-medicine context. The defensible chart includes a consent form that explicitly identifies the product, its FDA-approved indications, the off-label indication being treated, the evidence basis the practitioner relied on, the foreseeable risks discussed, and the patient's acknowledgment. For a regenerative product that is not FDA-approved for any indication — an exosome product, for example — the analysis is different: there is no "on-label" use to depart from, and the clinical use may itself fall outside FDA's enforcement position. Always consult a healthcare attorney before treating off-label with a regenerative product that does not have a clean approval status.

How ProofOps Medical helps Florida regenerative clinics

ProofOps' regenerative back-office reads from your EMR, your scheduling system, and your inventory layer to build the chain-of-custody, consent, GFE, supervisory-protocol, and inspection-response records that an FDA, AHCA, or Board of Medicine inspection asks for. The FDA warning letter index is checked weekly against your vendor list. The malpractice renewal exhibit is built 60 days before your carrier renews. The work happens under your medical director's direction and your healthcare attorney's review — we don't replace either.

Apply for Cohort Access and we'll map your specific regenerative documentation gaps before you commit — or Speak to a Florida Compliance Strategist. Prefer to start smaller? Take the secondary free Florida audit first.

Founding cohort — 2 of 5 Florida clinic slots remain.

This page is informational and reflects publicly available regulatory information as of May 2026. It is not legal advice, not medical advice, not a representation of the lawful clinical use of any specific regenerative product, and not a substitute for case-specific guidance from your medical director, your pharmacist (for compounded peptides), your malpractice broker, and a Florida-licensed healthcare attorney. Source material: 21 CFR Part 1271; FDA warning letter index; 21 USC § 352; Florida Statutes Chapter 458 (including §§ 458.331, 458.347, 458.348), Chapter 459, Chapter 464, § 456.47, § 400.9905; Florida Administrative Code Title 64B8; Florida Board of Medicine published guidance.